Rethinking Natural Products as a Source of Drug Leads

Rethinking Natural Products as a Source of Drug Leads

Tuesday, January 22, 2008

The New York Academy of Sciences

Organizers: Takushi Kaneko, TB Alliance and Vincent Gullo, Drew University

Join us as we examine the recent advances and future challenges in natural product chemistry. This symposium will address the evolution of natural product chemistry, in terms of unexplored sources of producing organisms, heterologous expression systems, and improved analytical/isolation methods.

Agenda

  • 1:00 pm
    Introduction and Symposium Theme
    Takushi Kaneko, PhD, TB Alliance
    Vincent Gullo, PhD, Drew University


  • 1:15 pm
    Developing a Drug-Like Natural Product Screening Library
    Ronald J. Quinn, PhD, Eskitis Institute, Griffith University, Brisbane, Australia


  • 2:00 pm
    Pathways for Natural Product Drug Discovery
    Guy T. Carter, PhD, Wyeth Research


  • 2:45 pm
    Coffee Break


  • 3:05 pm
    Turning the Tide of Natural Products Drug Discovery –
    Marine Microorganisms as a Source for New Drug Leads

    Ray Lam, PhD, Nereus Pharmaceuticals Inc.


  • 3:50 pm
    Novel Approaches for Antibiotic Discovery:
    Discovery of Platensimycin and Platencin

    Sheo B. Singh, PhD, Merck Research Laboratories


  • 4:35 pm
    80 Great Years of Microbial Natural Products;
    Is There a Future?

    Arnold L. Demain, PhD, Drew University


  • 5:20 pm
    Wrap-Up/Discussion

 

Abstracts

Developing a Drug-Like Natural Product Screening Library
Ronald J Quinn
Eskitis Institute, Griffith University, Brisbane, Australia

Modern drug discovery is based in large part on high throughput screening of small molecules against macromolecular disease targets. Current thinking in the generation of drug leads embodies the concept of achieving high molecular diversity within the boundaries of reasonable drug-like properties. Molecular screening libraries should contain drug-like or lead-like compounds.

Over millions of years of evolutionary pressure, natural products have been synthesised by biosynthetic enzymes. Natural products are privileged structures due to their recognition of biology space (protein surfaces).

We have recently discovered a correlation between the biosynthetic enzymes synthesising a particular natural product and the therapeutic target of the compound. This newest correlation provides the underlying reason why natural products are validated starting points for drug design and library development. 1-3.

We have analyzed known natural products for drug-like and lead-like properties. With this information in hand, we have established a strategy to screen drug-like or lead-like fractions. Our work has demonstrated that natural products extracts can be tuned into a lead-like or drug-like library by a combination of isolation and computational methods. This information has been instrumental in developing high throughput screening strategies for natural substances.

 

1) McArdle, B. M.; Campitelli, M. R.; Quinn, R. J., J. Nat. Prod. 2006, 69, 14-17.
2) McArdle, B. M., Quinn, R.J. ChemBioChem, 2007, 8, 788-798
3) Mitchell, J.K.; Pitcher, D.; McArdle, B.M.; Alnefelt, T.; Duffy, S.; Avery, V.; Quinn, R.J., Bioorg. Med. Chem. Lett. 2007, 17, 6521–6524.

Pathways for Natural Product Drug Discovery
Guy T. Carter, Wyeth Research

Natural products have historically been rich sources of biologically active compounds for drug discovery. This was particularly apparent during the so-called "golden age of antibiotics discovery" that occurred during the 1940's